Entries

Interim analysis from EMPRISE real-world study shows empagliflozin decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists

• This analysis on effectiveness also shows empagliflozin was associated with a similar risk of non-fatal atherosclerotic cardiovascular events compared with DPP-4 inhibitors or GLP-1 receptor agonists1• A second analysis on healthcare resource utilisation shows empagliflozin was associated with a reduced risk in all-cause hospitalisations compared with DPP-4 inhibitors2INGELHEIM, Germany and INDI...

Appendix

Profile

FC2MENA

Author:FC2MENA
Company of choice for regional and international news distribution in the region, chosen for our rapid response, comprehensive and unique service offering, strategic partnerships and affiliations, wide news coverage, and unbeatable returns.

Search form

QR code

QR